Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

Sharing Negotiated Discounts Could Save Patients More than $800 Annually and Would Increase Premiums About 1 Percent

October 12, 2017

Providing access to discounted medicine prices at the point of sale could save certain commercially insured patients with high deductibles and coinsurance $145 to more than $800 annually, according to a new analysis from Milliman that was commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Read More

Amgen Chairman and CEO Robert A. Bradway Elected PhRMA Board Chairman-Elect

October 11, 2017

The Pharmaceutical Research and Manufacturers of America elected new officers to its board of directors.

Read More

PhRMA to Present the 2017 Research & Hope Awards for Outstanding Mental Health Advocacy and Research

October 10, 2017

PhRMA today announced the recipients of the 2017 Research & Hope Awards.

Read More

PhRMA Announces Support for Seven-Day Script Limit on Opioid Medicines for Acute Pain

September 27, 2017

Pharmaceutical Research and Manufacturers for America CEO Stephen J. Ubl issued a statement.

Read More

PhRMA Statement on Commissioner Scott Gottlieb’s Address to the Regulatory Affairs Professionals Society 2017 Regulatory Conference

September 12, 2017

PhRMA director, Public Affairs, Andrew Powaleny issued a statement following U.S. FDA Commissioner Scott Gottlieb’s address to the Regulatory Affairs Professionals Society 2017 Regulatory Conference.

Read More

PhRMA and BIO Initiate Litigation to Challenge Unconstitutional Provisions of Nevada’s SB 539

September 1, 2017

Today, PhRMA and BIO initiated litigation challenging provisions of SB 539, a Nevada law that would violate patent rights and negate trade secret protection for designated diabetes medicines in a way that would harm patients and chill future biomedical innovation.

Read More

PhRMA Announces Dr. Richard Moscicki as New Chief Medical Officer and Executive Vice President

August 30, 2017

PhRMA today announced Richard A. Moscicki, M.D. will join the organization as chief medical officer and executive vice president.

Read More

PhRMA Statement on President Trump’s Signing of PDUFA VI Reauthorization

August 18, 2017

PhRMA president and CEO Stephen J. Ubl issued the following statement.

Read More

PhRMA Statement on Senate Passage of PDUFA VI Reauthorization

August 3, 2017

PhRMA applauds the Senate for passage of the Prescription Drug, Biosimilar and Generic Drug User Fee Acts.

Read More

New Report Shows 74 Percent of Medicines in Development have Potential to be First-in-Class Treatments

July 18, 2017

Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report.

Read More